Approved medicine, different product
Tirzepatide
Tirzepatide is a 39-amino-acid peptide, lipidated so that it lasts longer in circulation, and a dual agonist of the GIP and GLP-1 receptors. Licensed finished products exist. A research pen or vial is not one of them.
Research summary only. Not medical advice, not a protocol, and not for human or veterinary consumption.
- Also called
- LY3298176, Mounjaro (licensed brands), Zepbound (licensed brands)
- CAS
- 2023788-19-2
- Formula
- C225H348N48O68
- Sequence or structure
- 39-residue peptide acylated with a C20 fatty diacid
- Evidence
- Approved medicine, different product
Mechanism
It engages both incretin receptors. The fatty-diacid modification is part of the molecule, not an optional note. PubChem describes it as a linear polypeptide conjugated to a C20 fatty diacid through a linker on lysine.
Evidence
The US FDA has approved tirzepatide finished products for specified uses, including type 2 diabetes (sold as Mounjaro) and chronic weight management (sold as Zepbound). Those approvals attach to particular labelled products, strengths, devices, and quality systems. They do not attach to a research-supply vial.
Limitations
Do not describe this listing as Mounjaro or Zepbound. Do not copy a licensed dose ladder onto a research record just because the milligram numbers look familiar. Counter-ions change the weighed mass. Not for human consumption.
